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Background: There is limited data on results of central re-testing of samples from patients with invasive breast cancer categorised
in their local hospital laboratories as oestrogen receptor (ER) positive and human epidermal growth factor receptor homologue 2
(HER2) negative.
Methods: The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study (OPTIMA
prelim) was the feasibility phase of a randomised controlled trial to validate the use of multiparameter assay-directed
chemotherapy decisions in the UK National Health Service (NHS). Eligibility criteria included ER positivity and HER2 negativity.
Central re-testing of receptor status was mandatory.
Results: Of the 431 patients tested centrally, discrepant results between central and local laboratory results were identified in only 19
(4.4%; 95% confidence interval 2.5–6.3%) patients (with 21 tumours). On central review, seven patients had cancers that were ER-negative
(1.6%) and 13 (3.0%) patients with 15 tumours had HER2-positive disease, including one tumour discrepant for both biomarkers.
Conclusions: Central re-testing of receptor status of invasive breast cancers in the UK NHS setting shows a high level of
reproducibility in categorising tumours as ER-positive and HER2-negative, and raises questions regarding the cost effectiveness
and clinical value of central re-testing in this sub-group of breast cancers in this setting.
Oestrogen receptor (ER) and human epidermal growth factor
receptor homologue 2 (HER2) are established biomarkers in
invasive breast cancer and form the backbone of clinical decision-
making related to targeted therapies in the adjuvant setting.
Although data from external quality assurance schemes (such as
UK NEQAS ICC), successful participation in which is mandatory
for UK laboratories, indicates excellent performance for testing
these receptors in local laboratories nationally, there is relatively
little published evidence comparing local results to central re-
testing of local ER and HER2 expression in large clinical trial data
*Correspondence: Professor SE Pinder; Sarah.pinder@kcl.ac.uk
Received 29 September 2016; revised 4 January 2017; accepted 16 January 2017; published online 21 February 2017
r 2017 Cancer Research UK. All rights reserved 0007 – 0920/17
SHORT COMMUNICATION
Keywords: breast cancer; oestrogen receptor; HER2
British Journal of Cancer (2017) 116, 859–863 | doi: 10.1038/bjc.2017.28
www.bjcancer.com |DOI:10.1038/bjc.2017.28 859
sets. In particular, information from central laboratory testing/
validation of series of invasive breast carcinomas that have been
designated as ER-positive and HER2-negative is limited; reports
have largely described data from central re-testing of breast
cancers, which have been recorded as HER2-positive in local
laboratories such as in the Breast Intergroup Trial N9831 (Roche
et al, 2002; Perez et al, 2006). Some of these early publications have
indicated alarming proportions of discrepancy in defining HER2
positivity. There are fewer publications comparing central repeat
testing of hormone receptors from clinical trial samples but
Viale et al (2007) examined 6291 of 8010 tumours from women
in BIG1–98 and found that central review confirmed 97% of
tumours were hormone receptor-positive (defined as ER and/or
PgRX10%). Using tissue microarrays of tumours in the Tamoxifen
and Exemestane Adjuvant Multinational (TEAM) trial, of 4325
cases with sufficient material only 42 were ER-negative (0.99%), of
these 28 were PgR positive and only 14 ER-negative/PgR-negative
tumours were identified (0.3%; Bartlett et al, 2011b).
The accuracy of defining hormone receptor-positive and HER2-
negative invasive breast cancer in local centres is clearly vital for
patient management outside of the clinical trial setting, but also has
significant resource and cost implications within randomised trials
where ER and/or HER2 are critical components of eligibility. The
question remains whether local biomarker results are sufficiently
robust to allow trialists to avoid the costly re-analysis of
biomarkers in central laboratories to confirm patient eligibility.
To address this question we have examined data in the UK setting
within OPTIMA prelim.
MATERIALS AND METHODS
The Optimal Personalised Treatment of early breast cancer usIng
Multiparameter Analysis preliminary study (OPTIMA prelim)
(ISRCTN42400492) was the feasibility phase of a randomised
controlled trial designed to validate the use of multiparameter
assay-directed chemotherapy decisions in the UK National Health
Service (Bartlett et al, 2013, 2016; Stein et al, 2016). Patients were
agedX40 years at entry with surgically treated ER-positive, HER2-
negative primary invasive breast cancer, with 1–9 involved axillary
nodes or, if node negative, a tumour of at least 30mm in maximum
dimension. Patients were randomised to standard care (che-
motherapy followed by endocrine therapy) or an Oncotype DX test
(Genomic Health Inc., Redwood City, CA, USA) was performed on
the surgically resected tumour to assign patients either to standard
care (if ’Recurrence Score’ (RS) was425), or to endocrine therapy
alone (if RS wasp 25). In this feasibility study, ER and HER2 were
both re-assessed by a central laboratory (UCL Advanced
Diagnostics) after registration into the trial to confirm eligibility
prior to randomisation.
Oestrogen receptor was assessed centrally on whole tissue
sections by immunohistochemistry (6F11; Leica Biosystems,
Wetzlar, Germany) and an Allred score of 3 or more was regarded
as positive, as per national guidance at that time (Harvey et al,
1999). If central ER results were discordant with the local report,
and there was any doubt, the assay was repeated with a second
antibody (EP1, Dako, Santa Clara, CA, USA). Human epidermal
growth factor receptor homologue 2 was re-assessed centrally with
dual-colour dual-hapten brightfield in situ hybridisation (DDISH)
(Ventana Medical Systems, Tucson, AZ, USA) and, as per UK
National Guidelines, a ratio of Her2 to chromosome 17
centromeric probe (CEP17) of 2.00–2.20 was considered to
represent borderline/positive gene amplification, while a ratio of
Her2 : CEP17 of 42.20 was regarded as Her2 gene amplification
(Bartlett et al, 2011a). If DDISH proved unsuccessful, fluorescence
in situ hybridization (FISH) was attempted using the HER2
PathVysion probe (HER2 PathVysion; Abbott Molecular, Des
Plaines, IL, USA). Human epidermal growth factor receptor
homologue 2 immunohistochemistry (4B5; Ventana Medical
Systems) was applied in cases where no result was achievable by
either HER2 ISH technique.
RESULTS
Between October 2012 and August 2014, 442 patients were registered
into OPTIMA prelim, but 11 patients were subsequently withdrawn
prior to central testing. Thus a total of 431 patients, recruited from 35
sites, had their tumours tested centrally. Nineteen patients with 21
tumours showed discrepancies in receptor status between local and
central laboratory results (4.4%; 95% confidence interval 2.5–6.3%).
The remaining 412 patients (95.6%) with concordant results went on
to be randomised into OPTIMA prelim.
Seven tumours in seven patients (1.6%) were found to be ER-
negative on central re-testing (Table 1). Two of the seven were
heterogeneous, with an uncommon admixture of ER-negative and
ER-positive cells identified in the surgically excised tumour. Two
appear to represent true errors in local laboratory tests; as local
laboratory re-testing on the same sample found the tumours to indeed
be ER-negative (personal communication). In one case, an inter-
pretive difference remained between the local and central testing; the
core and the excision specimen were both re-assessed locally as
showing low-level ER expression (Allred score 3 in the core biopsy) by
the local pathologist. Unfortunately, despite liaison with the
laboratories it has not been possible to discover whether ER status
has been re-assessed locally for other two discrepant tumours.
Table 1. Details of the seven patients (from 431 patients registered and tested centrally) with discrepant oestrogen receptor
results
Central ER results
Patient ER status Allred score % Tumour cell positivity Comment
A Negative 0 0 Two clonality distinct tumours – part positive and part negative for ER.
Original ER on core biopsy.
B Negative 0 0 ER repeated in local laboratory on core biopsy using different antibody/
clone and negative staining for ER confirmed.
C Negative 0 0 ER retested locally and confirmed to be negative.
D Negative 0 0
E Negative 0 0 Heterogenous tumour, at least focally ER-negative.
F Negative 0 0
G Negative 0 0 Three tumours: two eligible, one ineligible
Abbreviation: ER¼oestrogen receptor.
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In total 15 tumours in 13 patients (3.0%) from the 431 patients
tested centrally were discrepant for HER2 results (Table 2). One
patient had one tumour that was centrally categorised as ER-
negative and also showed Her2 amplification (ratio of
Her2 : CEP17¼ 3.59). Seven others also showed Her2 amplification
(ratio of Her2 : CEP17 ranged from 2.39 to 3.92). An additional
patient had one tumour that was Her2 amplified and one tumour
that was borderline amplified (ratio of Her2 : CEP17¼ 2.78 and
2.11, respectively). The remaining four patients had tumours
showing borderline Her2 gene amplification (ratio between 2.00
and 2.20); including one patient with two tumours both showing
borderline amplification. Only 3 of the 15 tumours demonstrated
what some consider ‘high-level’ gene amplification (ratio 43.00)
(Starczynski et al, 2012) and none what others have described as
‘high-grade’ amplification (ratio X4.00; Seol et al, 2012).
It has not been possible to ascertain if there has been repeat HER2
testing (immunohistochemistry, or FISH or DDISH) on all of these 13
cases; for five women (with seven tumours) the local team have
managed the patient as per the central, HER2-positive, results without
apparent re-testing. In three further cases data have not been
obtainable. In four cases local re-testing has been undertaken: in two
cases (one by FISH, other method uncertain) the local laboratory
results have remained HER2-negative (both tumours borderline
amplified by Her2 : CEP17 ratio centrally), that is, results remaining
discrepant; one case was agreed to be HER2-positive by re-testing
locally by FISH; the final case on local repeat testing had a
Her2 : CEP17 ratio of42.00 but the local pathologist maintained that
the tumour should be regarded as HER2-negative because of low
average Her2 copy number. One case was negative immunohisto-
chemically but showed Her2 gene amplification (3.92).
DISCUSSION
Central re-testing of HER2-positive breast cancers has shown high
levels of variability in some clinical trials; for example, HER2
positivity was only confirmed in 85.8% of 2535 patients in the
North Central Cancer Treatment Group N9831 intergroup
adjuvant trial (Perez et al, 2006). Some of these trials, however,
pre-date stringent guidelines for HER2 assessment and reporting,
and the reasons for discordance are often not clear. The value
of central re-testing of breast cancers defined locally as HER2-
negative as an eligibility criterion for other, more recent, clinical
trials has not been well studied. Outwith clinical trials generally
lower degrees of discrepancy have been reported (Vani et al, 2008;
Kaufman et al, 2014), for example, Kaufman et al (2014) identified
that only 4% of 552 patients with metastatic HER2-negative
carcinoma (defined locally) in a large observational cohort were
HER2-positive on central re-testing. These data are essentially
similar to the results in our UK clinical trial where 3.5% of tumours
defined locally as HER2-negative were HER2-positive on central
re-analysis.
These data highlight that B3% of patients could be being
excluded from HER2-directed therapies due to a potentially
faulty local result in real-world testing in the United Kingdom.
However, of note, we report here the proportion of cases that
are discordant between local and central laboratory testing.
Although for two cases, repeat re-testing of the same samples
locally confirmed the tumour was ER-negative (rather than ER-
positive as initially reported), for others it is only possible to record
that the other results were ‘discordant’. It is not per se the case that
the central laboratory is correct and the local laboratory inaccurate,
as both adhere to the same quality assurance and reporting
guidelines.
Central repeat testing of hormone receptor status from clinical
trial samples have reported similar, albeit slightly higher, levels of
difference between local and central laboratories than we have
found. Viale et al (2007) examined 6291 of 8010 tumours
from women in BIG1–98 and found that central review confirmed
97% of tumours were hormone receptor-positive, although
this incorporated both ER and progesterone receptor, and with
different cut-offs than applied as routine in the United Kingdom
(i.e., defined as ER and/or PgRX10%). Indeed, the authors note










D Amplified 3.59 1.10 3.95 Also ER-negative on central testing
H Borderline amplified 2.00 2.78 5.55
I1a Borderline amplified 2.14 1.65 3.53
I2a Borderline amplified 2.06 1.69 3.47
J Borderline amplified 2.20 1.43 3.14
K Amplified 2.70 2.00 5.40
L Amplified 2.39 1.55 3.70
M Amplified 2.81 1.35 3.80 Heterogeneous – testing of core (locally)
and second block (centrally) showed Her2
non-amplified foci.
N Amplified 3.23 2.80 9.05
O1a Amplified 2.78 1.35 3.75
O2a Borderline amplified 2.11 1.40 2.95
P Amplified 2.45 1.10 2.70
Q Amplified 2.64 1.08 2.83
R Amplified 3.92 1.85 7.25
S Borderline amplified 2.11 2.03 4.30
Abbreviations: CEP17¼ chromosome 17 centromeric probe; ER¼oestrogen receptor; HER2¼human epidermal growth factor receptor homologue 2. Amplified: HER2 to CEP17 ratio42.20;
borderline amplified: HER2 to CEP17 ratio 2.00–2.20.
aG1 and G2, and N1 and N2, are tumours from the same patients, respectively.
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that, of 105 carcinomas that were reported locally as ER-negative,
73 had 410%, and 8 had 1–9% positive cells. This highlights the
difficulty of non-standard definitions globally for hormone
receptor positivity and the need for pathologists, as well as all
other members of the multidisciplinary team, to be aware of study
protocols and definitions.
Notwithstanding that these results compare favourably to the
(albeit limited) published data, there are a number of possible
explanations for discrepant results between local and central
laboratories. Additional challenges include variation in methodol-
ogy (e.g., immunohistochemistry vs FISH vs chromogenic in situ
hybridisation (DDISH) for assessment of HER2 status), as well as
differences in the antibody clones used, variation in the material
assessed (cores vs surgical excision specimens) and pathologist
interpretation. It is well recognised that variation between core
biopsy specimens and surgical excision is uncommon (o2% of
cases showing heterogeneity; Arnedos et al, 2009; Lee et al, 2012),
although this clearly does occur and may potentially explain
variations in receptor status if different specimens are submitted
for central testing than examined locally. Indeed, this variation
appears to explain at least two of the seven cases with discrepant
ER status in this study.
These potential discrepancies are all applicable even if the
central review is undertaken in ‘real time’, that is, prior to patient
randomisation, as in OPTIMA prelim. Nevertheless, particular care
must be taken when analysing historical data on ER status, even in
meta-analysis of clinical trials, or when comparing to present day
results; data extracted from local reports may be based on entirely
different methodologies; Collins et al (2008) examined (on TMA)
1851 cases where tissue and histology reports were available and
highlighted that in 82% of the cases the original assays were
biochemical. Even where immunohistochemistry was applied both
locally and centrally as the technique of choice, agreement was only
92% for ER status (310 of 336 specimens; Collins et al, 2008).
Again, the 1.6% difference seen in OPTIMA prelim compares
favourably.
Despite all the potential technical and interpretive differences in
biomarker analysis, the results from OPTIMA prelim indicate good
concordance between local laboratories and a central re-testing
centre in the United Kingdom in classification of invasive breast
cancers as ER-positive and HER2-negative. Such re-testing in large
randomised clinical trials recruiting thousands of patients is very
expensive and, in the setting of this group of patients (as opposed
to HER2-positive disease, for example, where discrepancies may be
higher), the value is questionable.
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